The Claim
Carriers of rare myostatin gene variants exhibit no significant association with alterations in follicle-stimulating hormone levels, age of menarche, age of menopause, number of live births, or risk of polycystic ovary syndrome.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare variations in the myostatin gene have the same levels of follicle-stimulating hormone, same age of first period and menopause, same number of children, and same risk of polycystic ovary syndrome as people without these variations.
See the scientific wording
Carriers of rare myostatin gene variants show no significant association with altered levels of follicle-stimulating hormone, age of menarche or menopause, number of live births, or risk of polycystic ovary syndrome, suggesting that myostatin disruption does not impair reproductive health in humans.
When the myostatin protein is disrupted, muscles grow larger and body fat decreases, but this change does not affect the hormones that control puberty, menstrual cycles, fertility, or ovarian function. The body's reproductive system continues to operate normally despite these muscle and fat changes.
What the research says
1 studyPeople born with a rare muscle-building gene mutation don't have problems with puberty, fertility, or hormone levels — their bodies just have more muscle and less fat, with no signs of reproductive issues.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.